NON-MEDICAL SWITCH BETWEEN ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS - A MULTICENTRE STUDY ON EFFICACY AND DRUG SUSTAINABILITY

被引：0
|
作者：
Lontai, Livia
Gonczi, Lorant
Balogh, Fruzsina
Komlodi, Nora
Resal, Tamas
Farkas, Klaudia
Molnar, Tamas
Miheller, Pal
Golovics, Petra A.
Schafer, Eszter
Szamosi, Tamas
Ilias, Akos
Lakatos, Peter L.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1507
引用
收藏
页码：S606 / S606
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
    Parisi, S.
    Becciolini, A.
    Ditto, M. C.
    Ariani, A.
    Ianniello, A.
    Priora, M.
    Paroli, M.
    Realmuto, C.
    Peroni, C. L.
    Di Vittorio, C. M. Centanaro
    Degiovanni, R.
    Lagana, A.
    Fusaro, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1295 - 1296
  • [32] The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
    Roxanne C. S. van Adrichem
    Hanneke J. E. Voorneveld
    Geeke J. Waverijn
    Marc R. Kok
    Radjesh J. Bisoendial
    Rheumatology and Therapy, 2022, 9 : 1109 - 1118
  • [33] The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
    van Adrichem, Roxanne C. S.
    Voorneveld, Hanneke J. E.
    Waverijn, Geeke J.
    Kok, Marc R.
    Bisoendial, Radjesh J.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1109 - 1118
  • [34] NON MEDICAL SWITCH FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILAR GP2017 IN PATIENTS AFFECTED BY CHRONIC ARTHRITIS
    Colaci, M.
    Aprile, M. L.
    La Rosa, A.
    Di Maggio, A.
    Malatino, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1135
  • [35] Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
    Hanzel, Jurij
    Jansen, Jeroen M.
    ter Steege, Rinze W. F.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (04) : 495 - 501
  • [36] Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study
    Wetwittayakhlang, Panu
    Karkout, Khaled
    Wongcha-um, Arti
    Tselekouni, Paraskevi
    Al-Jabri, Reem
    Afif, Waqqas
    Wild, Gary
    Bitton, Alain
    Bessissow, Talat
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 35 - 42
  • [37] Mandatory non-medical switching policy from originator to biosimilar infliximab in patients with inflammatory bowel disease in British Columbia: A cohort study
    Fisher, Anat
    Kim, Jason D.
    Dormuth, Colin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 133 - 133
  • [38] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Dutt, Krishneel
    Srinivasan, Ashish
    Van Langenberg, Daniel
    BIODRUGS, 2022, 36 (05) : 639 - 644
  • [39] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Krishneel Dutt
    Ashish Srinivasan
    Daniel Van Langenberg
    BioDrugs, 2022, 36 : 639 - 644
  • [40] Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
    Mazza, Stefano
    Sed, Nicole Piazza O.
    Conforti, Francesco Simone
    Fasci, Alberto
    Rimondi, Alessandro
    Marinoni, Beatrice
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Invernizzi, Pietro
    Girelli, Carlo
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Tontini, Gian Eugenio
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (01): : 172 - 181
12345